Incyte gets much-needed boost as eczema cream trial hits tar...

US biotech Incyte has announced positive topline results from a phase 3 trial of its ruxolitinib eczema cream in adults and adolescents aged 12 or above, sending its shares ticking up.

Lilly swoops on Dermira to claim Dupixent rival

Novartis’ $100m bet on eczema drug fails as MOR106 developme...

Galapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in atopic dermatitis (also known as eczema).

Pfizer’s Xeljanz follow-up abrocitinib gathers momentum

Sanofi's eczema drug gets EU approval to treat adolescents

The European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron's eczema drug Dupixent (dupilumab) to include adolescents, while new phase 3

Almirall takes option on Dermira's eczema drug lebrikizumab

Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, in a bid to take on Sanofi/Regeneron's recently approved Dupixent.